![](/images/Company_Logo/company_logo_default.png)
Nanospectra Biosciences Inc (AKA: Nanospectra ) Profile last edited on: 6/15/2021
CAGE: 3D4C0
UEI: CQEPCKVGYKX4
Business Identifier: Particle-based therapies for the selective and precise thermal destruction of solid tumors Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 09
County: Harris
Congr. District: 09
County: Harris
Public Profile
Nanospectra Biosciences is a medical device company pioneering a novel use of nanomedicine for selective thermal ablation. Anchored in intellectual property licensed from Rice University and collaborative research with scientists at MD Anderson Cancer Center, Nanospectra is commercializing a particle-based therapy for the precise thermal destruction of solid tumors. By allowing the systemically delivered particles to determine the zones of ablation -- rather than the placement of an energy source-- AuroLase Therapy can thermally ablate irregularly shaped tumors or inoperable tumors while minimizing damage to healthy adjacent tissue and preserving nearby critical structures.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2010 | 1 | NIH | $200,000 | |
Project Title: Tas::75 0849::Tas Targeted Photothermal Ablation of Melanoma | ||||
2010 | 1 | NIH | $200,000 | |
Project Title: Tas::75 0849::Tas Nanotechnology Imaging Agents Or Devices for Improved Detectio | ||||
2010 | 1 | NIH | $113,665 | |
Project Title: Real-Time Optical Feedback for the Control of in Vivo Nanoparticle Concentration | ||||
2009 | 1 | AF | $98,754 | |
Project Title: Laser Eye Protection for Visors Using Plasmon Resonant Particles | ||||
2009 | 1 | NSF | $149,296 | |
Project Title: Nanoparticle-Based Radio-Imaging and Ablation of Lung Cancer |
Key People / Management
David Jorden -- Interim CEO and Director
Michael Brawer -- Chief Medical Officer
Chris L Coleman
Glenn Goodrich -- Vice President, COO Process Development and Chemistry
Naomi Halas -- Co-Founder
Joseph B Jackson
Patrick D O'Neal
J Donald Payne -- former President
Jainxia Qiu
Jon Schwartz
Jon Alexander Schwartz -- Director, Clinical Research
Dan Watkins -- Co-Founder and Dircetor
Jennifer West -- Co-Founder & Board of Directors
Michael Brawer -- Chief Medical Officer
Chris L Coleman
Glenn Goodrich -- Vice President, COO Process Development and Chemistry
Naomi Halas -- Co-Founder
Joseph B Jackson
Patrick D O'Neal
J Donald Payne -- former President
Jainxia Qiu
Jon Schwartz
Jon Alexander Schwartz -- Director, Clinical Research
Dan Watkins -- Co-Founder and Dircetor
Jennifer West -- Co-Founder & Board of Directors
Company News
There are no news available.